Slingshot Insights recently conducted an interview with Dr. Bruce Bacon, Professor of Internal Medicine at Saint Louis University School of Medicine about the impact that Merck & Co., Inc. MRK 0.71%’s Zepatier will have on the HCV market, particularly when it comes to Gilead Sciences, Inc. GILD 2.28%‘s Harvoni and AbbVie Inc ABBV 0.36%‘s Viekira Pak.
When asked about his impression of Zepatier and its potential impact on the market, Dr. Bacon said he anticipates the drug playing a large role in the future of HCV treatment.
“The cure rates are excellent. It’s basically a genotype 1 and 4 treatment, it’s not for 2’s and 3’s, but we don’t see a lot of 2’s and 3’s, and we see hardly any 5’s and 6’s,” Dr. Bacon explained. “So, it’s pertinent to 80% of the patients that we see.”
When asked about how much market penetration Zepatier will achieve, Dr. Bacon noted…
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!